Nintedanib for progressive pulmonary fibrosis in real-world setting: an observational study comparing outcomes with an IPF cohort.

BMC Pulm Med · 2026 · PMC12905857 · PMID 41559703

Europe PMC DOI

hedged sentence

0.2160

closest p · 4.3× alpha

0.2160

boldest claim

The sentences

did not reach statistical significancep = 0.216not close (p > 0.1)

In contrast, 6MWTD decline in the PPF cohort showed a numerically greater reduction after nintedanib initiation (−20.30 m/year vs −61.09 m/year), but this difference did not reach statistical significance ( p = 0.216; Fig. 3 D).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.